On February 24, 2026, Great Expressions Dental Centers announced it had deployed VideaAI across its entire network of more than 210 offices — completing the rollout in just two weeks. That announcement came on the heels of similar deals with Heartland Dental and Aspen Dental, cementing VideaHealth's position as the enterprise clinical AI platform of record for the largest dental organizations in North America.
This is an independent editorial review. VideaHealth did not sponsor this article. We're covering it because the platform has reached a scale and adoption level that makes it impossible to ignore — and because practices at every size are starting to ask whether this is something they should be evaluating. Our job is to give you an honest breakdown before you're in a sales call.
What VideaHealth Is
VideaHealth is a Boston-based dental technology company founded in 2018 as an MIT spinout. Its commercial platform — now called VideaAI — launched in 2022 and has since grown to serve approximately 90,000 clinicians. The core product is an FDA-cleared AI platform that analyzes dental radiographs in real time, surfacing findings that might otherwise be missed or caught too late.
Unlike patient communication tools or scheduling platforms, VideaHealth operates at the clinical layer: it integrates with your imaging software and runs AI analysis on X-rays as they're taken chairside. The result is a second-opinion engine that flags potential pathology, annotates findings visually, and helps the dental team have a more confident, evidence-backed conversation with the patient about their treatment options.
The platform has three distinct modules: ClinicalAI (chairside diagnostics), WorkflowAI (documentation and charting automation), and EnterpriseAI (reporting, coaching, and performance visibility for multi-location organizations). Most practices start with ClinicalAI and layer in additional modules as they scale.
Those numbers come from VideaHealth's own published data and FDA trial results. Independent validation matters here: the 43% missed-lesion reduction is from the FDA clearance trial, which makes it more credible than typical vendor marketing claims. The 22% case acceptance increase is based on same-practice before/after comparisons — a reasonable methodology, though individual results will vary significantly based on how actively clinicians use the tool chairside.
What VideaAI Actually Does: The Three Modules
ClinicalAI — Chairside Diagnostics
This is the core product and the reason most practices adopt the platform. ClinicalAI analyzes bitewing and periapical X-rays in real time, detecting over 30 dental conditions including caries (tooth decay), periapical lesions (abscesses), calculus (tartar buildup), and periodontal bone loss. The AI presents findings as visual annotations directly on the radiograph — overlaid highlights that show the patient and the clinical team exactly where the system identified a potential issue.
The pediatric clearance is a notable differentiator: VideaAI received FDA clearance for caries detection in patients as young as three years old, making it one of the few platforms with formal regulatory approval for pediatric cases. This matters for practices with a significant pediatric patient mix and for larger DSOs looking for consistent clinical standards across all patient demographics.
The chairside experience is designed to strengthen patient trust rather than replace clinical judgment. When a patient can see an annotated X-ray with AI-flagged findings, treatment acceptance conversations become more visual and more concrete — "here's what the AI identified, here's what I see, here's what I recommend" is a different conversation than "you have a cavity on tooth 14."
WorkflowAI — Documentation & Automation
WorkflowAI handles the documentation and coding overhead that consumes significant time in a typical clinical workflow. The module automatically charts diagnosed conditions, suggests appropriate CDT codes, and surfaces untreated conditions from previous visits — what VideaHealth calls the "Videa Huddle" feature, which flags patients with open treatment plans before they arrive. VideaHealth reports that the platform saves approximately two hours per provider per day, primarily through automated documentation and coding support. That claim implies meaningful workflow changes — the kind that require actual adoption and consistent use to realize. Clinics that use the tool selectively will see proportionally less time savings.
EnterpriseAI — Multi-Location Visibility
EnterpriseAI is targeted at DSOs and multi-location groups. It provides cross-location performance reporting, clinical coaching tools, and aggregate visibility into diagnostic consistency across providers. For dental organizations that have grown through acquisition and want to establish clinical standards across a mixed provider base, this module addresses a real operational gap. It's also the primary reason that enterprise buyers — GEDC, Heartland, Aspen — find the platform compelling at scale: it provides the data layer needed to understand where diagnostic variation exists and where coaching or training interventions are warranted.
The Enterprise Adoption Story — And Why It Matters
The concentration of major DSO deals in a short window is notable and worth context. When GEDC (210 offices), Heartland Dental, and Aspen Dental all deploy the same clinical AI platform in rapid succession, a few things are happening:
- Enterprise due diligence validates the platform. Large DSOs have clinical operations teams, legal review, and procurement processes that scrutinize vendors carefully. When multiple enterprise buyers reach the same conclusion independently, it's a meaningful signal about platform maturity and clinical credibility — even if it doesn't guarantee fit for every practice type.
- Network effects accelerate adoption. As more DSOs deploy VideaAI, the platform's clinical database grows, FDA clearance profile strengthens, and the competitive pressure on the remaining holdouts increases. The enterprise tier is largely decided; the next phase of VideaHealth's growth will be the independent and mid-market segment.
- It creates a two-speed market. Large organizations that have deployed clinical AI will have different patient education capabilities, diagnostic consistency, and production data than practices that haven't. That gap will widen over the next 12–24 months. Independent practices aren't on a countdown clock, but the window to evaluate and implement before clinical AI becomes a baseline patient expectation is getting shorter.
That said, enterprise adoption doesn't automatically mean the platform is the right fit for an independent or small-group practice. The economics, implementation requirements, and feature set that make VideaAI compelling at 200+ locations look different when you're running two or three chairs. We'll address this in the Who It's Best For section below.
Pricing
VideaHealth does not publish pricing publicly. The platform is sold through a direct enterprise sales process, and pricing is customized based on practice size, location count, and which modules are deployed. For smaller practices, pricing typically starts in the range of a few hundred dollars per month per location, but enterprise contracts are negotiated on custom terms. Request a formal quote — do not rely on any third-party pricing estimates, including this article, for budgeting purposes.
What is generally understood about VideaHealth's pricing model:
- Enterprise/DSO pricing: Negotiated directly based on location count and contract term. Multi-year contracts are common at the DSO level. Volume pricing improves significantly with scale.
- Independent and small-group pricing: Available, typically on a per-location or per-provider basis. Pricing has reportedly become more accessible as the platform has matured and the company has focused on expanding beyond enterprise-only accounts.
- Module-based structure: ClinicalAI, WorkflowAI, and EnterpriseAI are separate layers. Practices that only need chairside diagnostics (ClinicalAI) pay less than those activating the full suite. Confirm exactly which modules are included in any quote you receive.
- Implementation costs: Integration with your imaging software and practice management system typically requires a setup and onboarding process. Ask about any one-time implementation fees before signing.
For a direct pricing comparison against peer platforms, see our 2026 dental AI comparison matrix — it covers VideaHealth alongside Pearl AI and other clinical AI platforms.
Pros & Cons
✓ Pros
- 35+ FDA-cleared AI indications — broadest regulatory clearance in dental AI
- Clinically validated: 43% reduction in missed lesions in FDA trial data
- 22% average case acceptance increase across same-practice comparisons
- Pediatric caries detection cleared for patients age 3+ — rare differentiator
- Real-time chairside analysis — findings surface during the appointment, not after
- Trusted by 8 of the 10 largest DSOs in North America — enterprise-proven platform
- Full platform: ClinicalAI + WorkflowAI + EnterpriseAI covers clinical, operational, and reporting needs
- Integrates with major imaging systems and practice management platforms
- 2 hrs/day per provider time savings reported from workflow automation
✗ Cons
- Pricing is not publicly available — requires a direct sales conversation and custom quote
- Enterprise-first heritage means smaller practices may find the sales process heavyweight
- ROI depends heavily on chairside adoption — tool value drops if clinicians use it inconsistently
- Per-location pricing at multi-site scale adds up — run the math before signing multi-year terms
- EnterpriseAI reporting module is built for DSO-scale visibility — limited value for single-location practices
- Does not address front-desk or scheduling workflows — it's a clinical layer, not a patient engagement platform
- Implementation requires integration with existing imaging software — confirm compatibility before committing
Who VideaAI Is Best For
Based on what the platform does and where its strongest documented results come from, here's an honest breakdown of who should seriously evaluate it:
- Multi-location DSOs and group practices. The EnterpriseAI module, multi-location reporting, and volume pricing structure are built for organizations running 10+ locations. The GEDC/Heartland/Aspen deployments represent this use case at maximum scale. If you're a DSO leader responsible for clinical consistency across sites, VideaAI is the current market benchmark — the comparison isn't whether to evaluate it, but how you structure the contract.
- Practices with a strong case acceptance problem. If your team is presenting treatment and patients are deferring at high rates, the chairside visual evidence provided by AI-annotated X-rays directly addresses the underlying trust and comprehension gap. The 22% case acceptance improvement isn't universal, but the mechanism — patients seeing annotated evidence rather than taking a provider's word for it — is sound.
- Practices concerned about diagnostic consistency across associate or part-time providers. Diagnostic variability is a real quality and liability issue in practices with rotating associates or high provider turnover. AI as a standardizing layer — applied to every X-ray regardless of which dentist is reading it — reduces the variance that comes from different clinical thresholds and experience levels.
- Practices that want early-adopter positioning. Clinical AI is moving from differentiator to baseline expectation at enterprise scale. Practices that implement and operationalize it now will have a 12–18 month head start on the independent and mid-market practices that are still evaluating. For high-volume practices in competitive markets, that window matters.
Who Should Be More Cautious
VideaAI isn't the right move for every practice at every moment. Here's when to slow down:
- Practices that haven't fixed their fundamental scheduling or patient flow problems. Clinical AI improves diagnosis and case acceptance — it doesn't fix a broken front desk, high no-show rates, or an understaffed hygiene department. If operational gaps are the primary constraint on production, those need to be addressed first. For a breakdown of patient engagement platforms that address scheduling and communication, see our PatientDesk AI review as a comparison point.
- Practices where adoption is uncertain. If your clinical team is skeptical of AI tools, or if the hygienists and dentists who would use VideaAI chairside haven't been involved in the evaluation, expect implementation friction. The ROI math on clinical AI assumes consistent, daily use. Practices with adoption risk should build a change management plan before signing — not after.
- Very low-volume single-operatory practices. The per-location cost structure and enterprise sales process may not be calibrated for practices running one or two chairs with a limited daily schedule. The time savings and case acceptance improvements at those volumes may not generate enough additional production to justify the investment. Ask specifically for a break-even analysis during your demo.
- Practices mid-transition on imaging systems. If you're already planning an imaging platform upgrade or PMS migration in the next 6–12 months, timing VideaAI integration with stable infrastructure reduces double implementation risk. Confirm integration compatibility with your current system before committing, and get clarity on what re-integration looks like if your imaging software changes.
How VideaHealth Compares to the Alternatives
VideaHealth operates in a small but growing segment of clinical AI platforms for dental radiology. The two main competitors at enterprise scale are Pearl AI and Overjet.
VideaHealth vs. Pearl AI
Pearl AI (Second Opinion®) is VideaHealth's closest direct competitor. Both platforms analyze dental radiographs with AI and present chairside findings. Pearl's differentiator has historically been its ADA-certified, peer-reviewed clinical foundation and a strong focus on diagnostic accuracy research. VideaHealth's differentiator is its FDA clearance breadth (35+ indications vs. Pearl's narrower clearance set), its pediatric detection capability, and — increasingly — its enterprise footprint. GEDC deployed VideaAI; DECA Dental (160+ offices) deployed Pearl. Both platforms are credible. The decision at the enterprise level often comes down to which platform wins the RFP and fits existing imaging infrastructure. At the independent practice level, both are worth a comparative demo. For the full breakdown, see our dental AI comparison matrix.
VideaHealth vs. Overjet
Overjet focuses heavily on insurance-side applications — AI-assisted claims documentation, coverage verification, and payer-facing radiology annotation. Where VideaHealth prioritizes chairside patient communication and clinical team support, Overjet prioritizes the revenue cycle and claims defensibility. For practices with a high insurance mix and a claims adjudication problem, Overjet may address a more immediate pain point. For practices primarily focused on improving diagnosis and case acceptance, VideaHealth's clinical-layer focus is more directly relevant.
Bottom Line
VideaHealth has earned its dominant position in enterprise dental AI. The FDA clearance breadth, the clinical trial data on missed lesion reduction, and the rapid adoption by the largest DSOs in North America are all meaningful signals that this is a mature, credible platform — not venture-backed vaporware.
The honest question for an independent or small-group practice isn't whether the platform works — it does, and the enterprise deployments confirm it. The question is whether the economics, the implementation commitment, and the clinical team adoption dynamics make sense at your specific scale and with your specific patient mix.
If you're running a high-volume practice, have a case acceptance problem, or manage multiple locations and want clinical consistency across providers, VideaAI should be on your short list. If you're a single-location practice where operational or scheduling problems are the bigger constraint, address those first — then revisit clinical AI when the foundation is stable.
Request a demo and ask for a site-specific ROI analysis — not a generic industry number. Get clarity on which modules are included in the quote, what the implementation timeline looks like with your existing imaging system, and what the minimum contract term is. If clinical AI is on your 2026 roadmap, VideaHealth is the most enterprise-validated option currently available. That doesn't mean it's the only option — it means it should be your benchmark for comparison when evaluating the field.
⚖️ Disclaimer: This is an independent editorial review. Practice Edge has no financial relationship with VideaHealth. Pricing information is based on publicly available sources and may not reflect current vendor pricing — verify directly with VideaHealth before making purchasing decisions. Performance statistics (FDA trial data, case acceptance figures) are sourced from VideaHealth's published materials and FDA clearance documentation; individual practice results will vary. This article does not constitute legal, compliance, clinical, or financial advice.